TAVR benefits high-risk patients with moderate aortic stenosis
In patients with moderate aortic stenosis with at least one at-risk feature, transcatheter aortic valve replacement was linked to reduced risk for death or a heart failure event at 2 years compared with clinical surveillance, data show.
“This is going to be a turning point in the way that we see patients with moderate aortic stenosis,” Philippe Généreux, MD, director of the structural heart program at Morristown Medical Center in New Jersey, said during a press conference at TCT 2026.
For the PROGRESS trial, simultaneously published in The New England Journal of Medicine, Généreux and